Ongoing Response in a Multiply Relapsed Metastatic Posterior Fossa Ependymoma A After Vorinostat and Concomitant Irradiation.
Journal of Pediatric Hematology/Oncology
Posterior fossa ependymomas A confer the worst prognosis among all subtypes. They demonstrate distinct epigenetic changes, which can be targeted with epigenetic modifiers like histone deacetylase inhibitors (Vorinostat). We describe a 3-year-old male diagnosed with a posterior fossa ependymoma who had a number of recurrences requiring multimodal therapy. Molecular analysis demonstrated a BCL-6 corepressor mutation, and methylation profiling matched with posterior fossa ependymomas A. He received craniospinal irradiation and focal boost with Vorinostat. Serial imaging after irradiation revealed a progressively decreasing tumor burden with nearly complete resolution of disease at 15 months. Histone deacetylase inhibitors demonstrate promise in treatment of carefully selected cases of ependymoma.
Gorsi HS, Toll SA, Sood S, Miler S, Altinok D, Kumar-Sinha C, et al [Yankelevich M] Ongoing response in a multiply relapsed metastatic posterior fossa ependymoma A after vorinostat and concomitant irradiation. J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e576-e579. doi: 10.1097/MPH.0000000000002175. PMID: 33930008.